
Would you like to receive update from CareSync Experts?
Summary, notice description and lot information
The NHS Greater Manchester Integrated Care Board has completed a procurement process for the assessment and treatment of adults with ADHD across Oldham, Bury, and Rochdale. The contract, classified under the industry category of Psychiatrist or psychologist services (CPV code 85121270), involves a limited award procedure without prior publication of a call for competition. The awarded contract, running from 1st April 2025 to 31st March 2026, is valued at £1,146,000 and addresses the urgent need for neurodevelopmental assessments and ongoing medication reviews to ensure continuity of care for patients.
This procurement utilised Regulation 14 of the Provider Selection Regime and falls outside the scope of the standard procurement regulations. This tender presents significant opportunities for healthcare providers specializing in neurodevelopmental disorders, particularly those experienced in ADHD treatment. Optimise Healthcare Group, a large business based in Warrington, has been awarded the contract, underlining the potential for other similar entities to engage in future opportunities in this sector.
Businesses with expertise in medical assessments, medication management, and patient care continuity would be well-positioned to compete for similar contracts, allowing them to expand their services and client base within the UK’s healthcare industry.
An urgent award is required to enable timely assessment to those deemed to require this and to maintain continuity of care for the patients currently in titration or under shared care. There is a high clinical risk to patients who require ongoing medication reviews and assessments in the event of any disruption in treatment. Patients can only be initiated on ADHD medication by a specialist provider and can only be prescribed ADHD medication in primary care under shared care arrangements with a specialist provider. This is because the medications are classed as AMBER drugs under the GMMMG Formulary. Patients on these drugs are required to have routine medication reviews by the specialist service to maintain safe prescribing. This contract is for 12 months from 1st April 2025 - 31st March 2026. The maximum contract value will be PS1,146,000. Award decision-makers: Corporate Director of Finance - Commissioning & Financial Assurance and the Executive Committee on behalf on NHS Greater Manchester Integrated Care Board. No conflicts or potential conflicts of interest of the individuals making the decision identified. The procurement falls outside the scope of application of the regulations.
Notice type, method, and CPV codes
Financial information and value estimates
Contract duration information not available.
Publication, submission, and award timeline
Current status of tender, lots, awards, and contracts
Buyer organisation and contact details
Supplier who was awarded this contract
External resources and data downloads
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector.
Our expert team can help you prepare a winning bid. Get professional support from CareSync Experts.
Get in touch with our team at Care Sync Experts today for a consultation.
Email: hello@caresyncexperts.co.uk
Phone: 0333 577 0877
Contact Us